China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. More Details
High growth potential with excellent balance sheet.
Share Price & News
How has China Isotope & Radiation's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1763 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 1763's weekly volatility (11%) has been stable over the past year.
7 Day Return
HK Medical Equipment
1 Year Return
HK Medical Equipment
Return vs Industry: 1763 exceeded the Hong Kong Medical Equipment industry which returned 43.4% over the past year.
Return vs Market: 1763 exceeded the Hong Kong Market which returned 28.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is China Isotope & Radiation's share price compared to the market and industry in the last 5 years?
Simply Wall St News
22 hours ago | Simply Wall StCan Mixed Fundamentals Have A Negative Impact on China Isotope & Radiation Corporation (HKG:1763) Current Share Price Momentum?
2 weeks ago | Simply Wall StChina Isotope & Radiation (HKG:1763) Has A Pretty Healthy Balance Sheet
1 month ago | Simply Wall StOur Take On The Returns On Capital At China Isotope & Radiation (HKG:1763)
Is China Isotope & Radiation undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1763 (HK$27.8) is trading above our estimate of fair value (HK$3.88)
Significantly Below Fair Value: 1763 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1763 is poor value based on its PE Ratio (34.9x) compared to the HK Medical Equipment industry average (29.9x).
PE vs Market: 1763 is poor value based on its PE Ratio (34.9x) compared to the Hong Kong market (11.8x).
Price to Earnings Growth Ratio
PEG Ratio: 1763 is poor value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: 1763 is good value based on its PB Ratio (1.9x) compared to the HK Medical Equipment industry average (3x).
How is China Isotope & Radiation forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1763's forecast earnings growth (33.9% per year) is above the savings rate (1.5%).
Earnings vs Market: 1763's earnings (33.9% per year) are forecast to grow faster than the Hong Kong market (18.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1763's revenue (20.4% per year) is forecast to grow faster than the Hong Kong market (13.3% per year).
High Growth Revenue: 1763's revenue (20.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1763's Return on Equity is forecast to be low in 3 years time (13.6%).
How has China Isotope & Radiation performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1763 has high quality earnings.
Growing Profit Margin: 1763's current net profit margins (5%) are lower than last year (8.2%).
Past Earnings Growth Analysis
Earnings Trend: 1763's earnings have declined by 0.08% per year over the past 5 years.
Accelerating Growth: 1763's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1763 had negative earnings growth (-35%) over the past year, making it difficult to compare to the Medical Equipment industry average (19.7%).
Return on Equity
High ROE: 1763's Return on Equity (8.6%) is considered low.
How is China Isotope & Radiation's financial position?
Financial Position Analysis
Short Term Liabilities: 1763's short term assets (CN¥5.8B) exceed its short term liabilities (CN¥2.8B).
Long Term Liabilities: 1763's short term assets (CN¥5.8B) exceed its long term liabilities (CN¥907.5M).
Debt to Equity History and Analysis
Debt Level: 1763's debt to equity ratio (12%) is considered satisfactory.
Reducing Debt: 1763's debt to equity ratio has increased from 4.6% to 12% over the past 5 years.
Debt Coverage: 1763's debt is well covered by operating cash flow (44%).
Interest Coverage: 1763 earns more interest than it pays, so coverage of interest payments is not a concern.
What is China Isotope & Radiation current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 1763's dividend (0.77%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.95%).
High Dividend: 1763's dividend (0.77%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.98%).
Stability and Growth of Payments
Stable Dividend: 1763 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Growing Dividend: 1763 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 1763 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1763's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
China Isotope & Radiation has no CEO, or we have no data on them.
Experienced Management: 1763's management team is considered experienced (4.2 years average tenure).
Experienced Board: 1763's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
China Isotope & Radiation Corporation's company bio, employee growth, exchange listings and data sources
- Name: China Isotope & Radiation Corporation
- Ticker: 1763
- Exchange: SEHK
- Founded: 1983
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: HK$8.797b
- Shares outstanding: 319.87m
- Website: https://www.circ.com.cn
Number of Employees
- China Isotope & Radiation Corporation
- Building 1
- No. 66 Changwa Middle Street
- Beijing Province
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and indus...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/19 10:11|
|End of Day Share Price||2021/04/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.